Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms
| Author | Bertok, Tomas |
| Author | Jane, Eduard |
| Author | Chrenekova, Nikola |
| Author | Hroncekova, Stefania |
| Author | Bertokova, Aniko |
| Author | Hires, Michal |
| Author | Vikartovska, Alica |
| Author | Kubanikova, Petra |
| Author | Sokol, Roman |
| Author | Fillo, Juraj |
| Author | Kasak, Peter |
| Author | Borsig, Lubor |
| Author | Tkac, Jan |
| Available date | 2025-03-10T08:18:50Z |
| Publication Date | 2020 |
| Publication Name | Glycoconjugate Journal |
| Resource | Scopus |
| Identifier | http://dx.doi.org/10.1007/s10719-020-09958-4 |
| ISSN | 2820080 |
| Abstract | This is the first work focused on glycoprofiling of whole N- and O- glycome using lectins in an array format applied for analysis of serum samples from healthy individuals, benign prostate hyperplasia (BPH) patients, and prostate cancer (PCa) patients. Lectin microarray was prepared using traditional lectins with the incorporation of 2 recombinant bacterial lectins and 3 human lectins (17 lectins in total). Clinical validation of glycans as biomarkers was done in two studies: discrimination of healthy individuals with BPH patients vs. PCa patients (C vs. PCa) and discrimination of healthy individuals vs. BPH and PCa patients (H vs. PCond). Single lectins (17 lectins) and a combination of two lectins (136 binary lectin combinations) were applied in the clinical validation of glycan biomarkers providing 153 AUC values from ROC curves for both studies (C vs. PCa and H vs. PCond). Potential N- and O-glycans as biomarkers were identified and possible carriers of these glycans are shortly discussed. |
| Sponsor | Funding text 1: The authors would like to acknowledge the financial support received from VEGA 2/0130/20 and the Slovak Research and Development Agency APVV 17-0300 and APVV-15-0227. We would like to acknowledge the support received from the Ministry of Health of the Slovak Republic under the project registration number 2019/68-CH�SAV-1. This publication was supported by Qatar University Grants IRCC-2020-004. The statements made herein are solely the responsibility of the authors. This publication was created with the support of the Operational Program Integrated Infrastructure for the project: Center for Biomedical Research - BIOMEDIRES - II. stage, ITMS: 313011W428, co-financed by the European Regional Development Fund. ; Funding text 2: The authors would like to acknowledge the financial support received from VEGA 2/0130/20 and the Slovak Research and Development Agency APVV 17?0300 and APVV-15-0227. We would like to acknowledge the support received from the Ministry of Health of the Slovak Republic under the project registration number 2019/68-CH?SAV-1. This publication was supported by Qatar University Grants IRCC-2020-004. The statements made herein are solely the responsibility of the authors. This publication was created with the support of the Operational Program Integrated Infrastructure for the project: Center for Biomedical Research - BIOMEDIRES - II. stage, ITMS: 313011W428, co-financed by the European Regional Development Fund. |
| Language | en |
| Publisher | Springer |
| Subject | Clinical validation Diagnostics Lectin microarrays N- and O-glycome Prostate cancer Serum |
| Type | Article |
| Pagination | 703-711 |
| Issue Number | 6 |
| Volume Number | 37 |
Files in this item
This item appears in the following Collection(s)
-
Center for Advanced Materials Research [1441 items ]